Omalizumab Rescue Therapy for Refractory Status Asthmaticus
Authors: Katrin Milger, Ines Schroeder, Jürgen Behr, Tobias Meis, Werner v. Wulffen, Nikolaus Kneidinger
Journal: Annals of Internal Medicine (2018)

Letters5 March 2019Omalizumab Rescue Therapy for Refractory Status AsthmaticusKatrin Milger, MD, Ines Schroeder, MD, Jürgen Behr, MD, Tobias Meis, MD, Werner v. Wulffen, MD, PhD, and Nikolaus Kneidinger, MD, PhDKatrin Milger, MDLudwig-Maximilians-University of Munich and Comprehensive Pneumology Center, Munich, Germany (K.M., J.B., N.K.), Ines Schroeder, MDLudwig-Maximilians-University of Munich, Munich, Germany (I.S.), Jürgen Behr, MDLudwig-Maximilians-University of Munich and Comprehensive Pneumology Center, Munich, Germany (K.M., J.B., N.K.), Tobias Meis, MDKlinik Augustinum München, Munich, Germany (T.M., W.V.W.), Werner v. Wulffen, MD, PhDKlinik Augustinum München, Munich, Germany (T.M., W.V.W.), and Nikolaus Kneidinger, MD, PhDLudwig-Maximilians-University of Munich and Comprehensive Pneumology Center, Munich, Germany (K.M., J.B., N.K.)Author, Article, and Disclosure Informationhttps://doi.org/10.7326/L18-0359 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Background: Despite advances in asthma therapy, asthma mortality has remained stable in recent years (1). One reason is status asthmaticus, which can be unresponsive to initial treatment and may lead to hypercapnic respiratory failure despite maximal therapy.Objective: To alert clinicians to the possibility of a new rescue option for status asthmaticus.Case Report: A 41-year-old man developed severe dyspnea while working at an outside construction site. The patient had a history of asthma with pollen allergy. He had not consulted a respiratory physician recently but had been using a short-acting β2-agonist inhaler several times daily for several weeks. The ...References1. Ebmeier S, Thayabaran D, Braithwaite I, Bénamara C, Weatherall M, Beasley R. Trends in international asthma mortality: analysis of data from the WHO Mortality Database from 46 countries (1993-2012). Lancet. 2017;390:935-45. [PMID: 28797514] doi:10.1016/S0140-6736(17)31448-4 CrossrefMedlineGoogle Scholar2. Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa GD, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol. 2001;108:184-90. [PMID: 11496232] CrossrefMedlineGoogle Scholar3. Busse WW, Morgan WJ, Gergen PJ, Mitchell HE, Gern JE, Liu AH, et al. Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. N Engl J Med. 2011;364:1005-15. [PMID: 21410369] doi:10.1056/NEJMoa1009705 CrossrefMedlineGoogle Scholar4. Corne J, Djukanovic R, Thomas L, Warner J, Botta L, Grandordy B, et al. The effect of intravenous administration of a chimeric anti-IgE antibody on serum IgE levels in atopic subjects: efficacy, safety, and pharmacokinetics. J Clin Invest. 1997;99:879-87. [PMID: 9062345] CrossrefMedlineGoogle Scholar5. Coyle AJ, Wagner K, Bertrand C, Tsuyuki S, Bews J, Heusser C. Central role of immunoglobulin (Ig) E in the induction of lung eosinophil infiltration and T helper 2 cell cytokine production: inhibition by a non-anaphylactogenic anti-IgE antibody. J Exp Med. 1996;183:1303-10. [PMID: 8666888] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: Ludwig-Maximilians-University of Munich and Comprehensive Pneumology Center, Munich, Germany (K.M., J.B., N.K.)Ludwig-Maximilians-University of Munich, Munich, Germany (I.S.)Klinik Augustinum München, Munich, Germany (T.M., W.V.W.)Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=L18-0359.This article was published at Annals.org on 20 November 2018. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byStatus Asthmaticus GravidusAdministration of benralizumab in a patient with severe asthma admitted to the intensive care unit with COVID-19 pneumonia: case reportRescue therapy for refractory status asthmaticus with updosed omalizumab adjusted for IgE level, body weight and effectSuccessful treatment of refractory status asthmaticus with omalizumab: a case reportRecent Advances in Severe AsthmaManagement of Status AsthmaticusCase Report: Acute effect of benralizumab on asthma exacerbation without concomitant corticosteroid useReslizumab in an invasively ventilated patient with acute respiratory failure 5 March 2019Volume 170, Issue 5Page: 351-352KeywordsAsthmaBody weightDisclosureEosinophilsExtracorporeal membrane oxygenationLungsMagnesiumPollenRespiratory failureVentilators ePublished: 20 November 2018 Issue Published: 5 March 2019 Copyright & PermissionsCopyright © 2018 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...